Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Silica is a proven and highly effective anti-caking agent that has been used for decades
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Subscribe To Our Newsletter & Stay Updated